Inhibitors of bacterial type III secretion system
Organic compounds showing the ability to inhibit effector toxin secretion or translocation mediated by bacterial type III secretion systems are disclosed. The disclosed type III secretion system inhibitor compounds are useful for combating infections by Gram-negative bacteria such as Salmonella spp., Shigella flexneri, Pseudomonas spp., Yersinia spp., enteropathogenic and enteroinvasive Escherichia coli , and Chlamydia spp. having such type III secretion systems.
1. A method for treating an individual infected with a Gram-negative bacterium comprising administering to said individual an effective amount to inhibit T3SS-mediated effector secretion of a compound selected from the group consisting of:
2. The method of claim 1 , wherein said compound is selected from the group consisting of:
3. The method according to claim 1 , wherein said individual is human.
4. The method according to claim 1 , wherein said Gram-negative bacterium is of the genus Pseudomonas, Salmonella, Yersinia , or Chlamydia.
5. The method according to claim 1 , wherein said Gram-negative bacterium is Pseudomonas aeruginosa, Yersinia pestis or Chlamydia trachomatis.
6. The method according to claim 1 , wherein said Gram-negative bacterium is Pseudomonas aeruginosa.
7. The method according to claim 1 , further comprising administering an additional active ingredient selected from the group consisting of an antibiotic, an antibody, an antiviral agent, an anticancer agent, an analgesic, an immunostimulatory agent, a natural, synthetic or semi-synthetic hormone, a central nervous system stimulant, an antiemetic agent, an anti-histamine, an erythropoietin, a complement stimulating agent, a sedative, a muscle relaxant agent, an anesthetic agent, an anticonvulsive agent, an antidepressant, an antipsychotic agent, and combinations thereof.